Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.